# A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Source: https://onco.cc/trials/nct04640545/  
OnCo record `nct04640545` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.

## Summary

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma is a phase 1 interventional study registered as NCT04640545 by Nanjing Leads Biolabs Co.,Ltd, with 79 participants enrolled, started 2020-05-12. Conditions recorded: Advanced Melanoma. Interventions recorded: LBL-007, Toripalimab and Axitinib Tablets.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04640545
- Phase: 1
- Setting: A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 79

## Sources

- ClinicalTrials.gov NCT04640545: https://clinicaltrials.gov/study/NCT04640545

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct04640545.json